TMN 355 is a potent cyclophilin A inhibitor (IC50 = 1.52 nM). Approximately 27 times more potent than cyclosporin A.
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | 8-week-old male C57/BL6 MCD diet mice |
| Formulation | vehicle (DMSO) |
| Dosages | 10 mg/kg or 20 mg/kg |
| Administration | intraperitoneally |
| Molecular Weight | 380.8 |
| Formula | C21H14ClFN2O2 |
| CAS Number | 1186372-20-2 |
| Solubility (25°C) | DMSO 15.23 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related Cyclophilin Products |
|---|
| Rencofilstat
Rencofilstat (CRV431) is a cyclosporine derivative as well as an orally active cycloheximide (CYPA) inhibitor for studies related to non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma. |
| CypD-IN-3
CypD-IN-3 is a potent and subtype-selective cyclophilin D (CypD) inhibitor. CypD-IN-3 has CypD affinity with an IC50 value of 0.01 μM. CypD-IN-3 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes. |
| ASP5286
ASP5286 is a novel non-immune cyclophilin inhibitor for the study of HCV. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
